Lippincott Journals Subscribers, use your username or email along with your password to log in.
Registered users can save articles, searches, and manage email alerts.
All registration fields are required.
Flash Player 9.0.0 is required for the Video Gallery.
Get Adobe Flash Player.
Friend's E-mail is Invalid
Your message has been successfully sent to your friend.
Oncology Times. 36(3):32, February 10th, 2014
Professor Hans Wildiers, MD, PhD, from the University Hospitals Multidisciplinary Breast Centre in Leuven, Belgium, explains why TDM-1 doubles progression-free survival in HER2-positive advanced refractory breast cancer.